Haemophilus Influenzae Type B-Diseases

2021 ◽  
Author(s):  
Heinz-J. Schmitt ◽  
Khrystyna Hrynkevych

Haemophilus influenzae is a small Gram negative coccobacillus colonizing the respiratory tract of humans. The bacterium may cause direct local infections like otitis media, as well as severe invasive diseases like meningitis. In the prevaccine era, of the 6 capsular serotypes (a–f), type b caused the majority of invasive disease cases, whereas “nontypeable H. influenzae” (NTHi) and other capsular types predominate today. H. influenzae infections affect mainly children <5 years as well as persons >60 years with underlying diseases like COPD. Diagnosis of Hib disease is performed by classical microbiological culture techniques, antigen detection tests and polymerase chain reaction from blood samples, CSF or puncture samples. If untreated or if treatment is delayed, invasive Hib diseases may result in severe consequences such as hearing loss, chronic seizures, learning disabilities, and even death. Safe and effective polysaccharide-conjugate vaccines have been available for children for almost 30 years, reducing invasive Hib-incidences from about 60 to <1 / 105. Today, largely DTP-based Hib-combinations are used. After the primary series with 2 or 3 doses depending on the product and local recommendations, a booster dose in the second year of life is needed to ensure long-term protection.

1993 ◽  
Vol 38 (1) ◽  
pp. 18-20 ◽  
Author(s):  
A Coggins ◽  
C.W. Shepherd ◽  
F. Cockburn

The objective of this study was to investigate the epidemiology of invasive disease due to Haemophilus influenzae type b in childhood in Glasgow. A retrospective study has been made on the hospital records of 252 children aged 0 to 12 years admitted to Glasgow hospitals during 1981–1990. The annual incidence of invasive Haemophilus influenzae type b disease in Glasgow was estimated at 39 per 100,000 children less than five years of age per year. The figure for Haemophilus meningitis was 23.8 per 100,000 children less than five years of age per year. Ninety-five per cent of all cases occurred in children less than five years of age and 72.1% of meningitis cases occurred before two years of age. There was a mortality of 2.77%. Long-term neurological sequelae were found in 15.3% of the survivors. The annual incidence of Haemophilus influenzae type b disease is slightly higher in Glasgow than previously reported for the United Kingdom. The study provides baseline data to help assess efficacy of proposed early childhood vaccination.


Vaccine ◽  
2017 ◽  
Vol 35 (46) ◽  
pp. 6297-6301 ◽  
Author(s):  
Domenico Martinelli ◽  
Chiara Azzari ◽  
Paolo Bonanni ◽  
Susanna Esposito ◽  
Elisabetta Franco ◽  
...  

PEDIATRICS ◽  
1990 ◽  
Vol 85 (4) ◽  
pp. 698-704
Author(s):  
Sunil K. Sood ◽  
Robert S. Daum

Several Haemophilus influenzae type b vaccines have been licensed and recommended for administration to children in the United States. These vaccines have consisted of purified polyribosylribitol-phosphate (PRP), the capsular polysaccharide of H influenzae type b,1 alone or covalently bound to one of several carrier proteins. Two of these saccharide-protein conjugate vaccines are now licensed, a polysaccharide-diphtheria toxoid conjugate (PRP-D)2 and an oligosaccharide-mutant diphtheria toxin conjugate (HbOC).3 Two others, a polysaccharide- Neisseria meningitidis outer membrane protein conjugate (PRP-OMPC)4 and a polysaccharide-tetanus toxoid conjugate (PRP-T),5 are currently in clinical trials. One concern with the use of PRP vaccine was the suggestion that the incidence of invasive disease caused by H influenzae type b in the immediate period after immunization might be increased; this idea was supported by evidence from several sources. In a case-control study of the efficacy of PRP vaccine, Black et al6 found that 4 children were hospitalized for invasive disease within 1 week of immunization, a rate of invasive disease 6.4 times greater (95% confidence interval [CI], 2.1 to 19.2) than the background rate in unvaccinated children. In Minnesota, the relative risk for invasive disease in the first week after immunization was 6.2 (95% CI, 0.6 to 45.9),7 and the results of a study conducted by the Centers for Disease Control in six areas of the United States revealed a 1.8-fold (95% CI, 0.3 to 10.2) increase in the occurrence of invasive disease caused by H influenzae type b in the first week after immunization.8 Moreover, among 16 cases of disease caused by H influenzae type b occurring within 14 days of immunization that were passively reported to the FDA,9 10 were clustered within the first 72 hours.


PEDIATRICS ◽  
1994 ◽  
Vol 93 (4) ◽  
pp. 680-681
Author(s):  
Laurence B. Givner ◽  
Charles R. Woods ◽  
Jon S. Abramson

The practice of pediatrics is forever altered when a vaccine is effective in dramatically reducing the incidence of (or even eradicating) an infectious disease. As the targeted disease is rapidly declining in incidence, there are often exciting changes in the practice of pediatrics, with far-reaching effects in the everyday treatment of patients. Such is the case now due to the effectiveness of the conjugated polysaccharide vaccines against Haemophilus influenzae type b (Hib). The resultant rapid decline in the incidence of invasive disease due to Hib during the past several years has been documented in numerous studies.1-3 The effects of this dramatic decline in Hib disease on the approach to children who have (presumed) infectious diseases are the subject of this editorial.


2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Maria Del Valle Juarez ◽  
Carolina Rancaño ◽  
Silvina Neyro ◽  
Cristian Biscayart ◽  
Nathalia Katz ◽  
...  

2002 ◽  
Vol 129 (1) ◽  
pp. 73-83 ◽  
Author(s):  
T. LEINO ◽  
K. AURANEN ◽  
P. H. MÄKELÄ ◽  
H. KÄYHTY ◽  
M. RAMSAY ◽  
...  

Natural immunity to Haemophilus influenzae type b (Hib) invasive disease is based on antibodies arising in response to encounters with Hib or cross-reactive (CR) bacteria. The relative importance of Hib and CR contacts is unknown. We applied a statistical model to estimate the total rate of immunizing infections of Hib and CR prior to wide-scale vaccinations in Finland and the UK. The average rates of these contacts were 0.7 and 1.2 per year per child in Finland and the UK, respectively. Using a rough estimate of 0.1 Hib acquisitions per year per child in the UK based on carriage rates, the proportion of Hib among all immunizing contacts was in the order of 10%, suggesting that CR bacteria have a major role. In general, varying frequency of CR contacts may explain some differences in the pre-vaccination incidence and age-distribution of invasive disease in different countries.


1987 ◽  
Vol 14 (3) ◽  
pp. 233-236 ◽  
Author(s):  
J. Eskola ◽  
A. Takala ◽  
H. Käyhty ◽  
M. Leinonen ◽  
T. Kilpi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document